Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs,
targeted therapeutic drugs have become mainstream cancer treatments. Since the first …

Objective To understand the role of the genetic changes and bone marrow
microenvironment on the development, progression, and staging of multiple myeloma (MM) …

Venetoclax is a selective, orally bioavailable BCL-2 inhibitor that induces cell death in
multiple myeloma (MM) cells, particularly in those harboring t (11; 14), which express high …

The antiapoptotic proteins BCL-2 and myeloid cell leukemia sequence 1 (MCL-1) promote
multiple myeloma (MM) cell survival. Venetoclax is a selective, orally bioavailable small …

Apoptosis is critical for maintaining bodily homeostasis and produces a large number of
apoptotic extracellular vesicles (apoEVs). Several types of cancer cells display reduced …

Acute myeloid leukemia (AML) is a highly heterogeneous hematopoietic malignancy
characterized by excessive proliferation and accumulation of immature myeloid blasts in the …

The immunomodulatory drugs (IMiDs) thalidomide, lenalidomide, and pomalidomide, all
approved for the treatment of multiple myeloma, induce targeted ubiquitination and …

Numerous studies confirmed that aberrant miRNAs expression contributes to multiple
myeloma (MM) development and progression. However, the roles of specific miRNAs in MM …

The outcomes of multiple myeloma (MM) have been improved significantly with the
therapies incorporating proteasome inhibitors (PI), immunomodulatory drugs, monoclonal …

Graft versus host disease (GVHD) remains a major cause of morbidity and mortality
following allogeneic hematopoietic stem-cell transplantation (HSCT). Despite the use of …